Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03232138 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial of Lung Cancer Chemoprevention With Sulforaphane in Former Smokers
A Phase 2 study of Lung Cancer, sponsored by Jian-Min Yuan, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT03232138: Completed Phase 2 study of Lung Cancer, sponsored by Jian-Min Yuan, MD.
NCT03232138 is a Phase 2 study of Lung Cancer that has completed, run by Jian-Min Yuan, MD. The registered enrollment target is 43 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03232138, a Phase 2 study of Lung Cancer, has completed, sponsored by Jian-Min Yuan, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study involves taking an experimental anti-cancer dietary supplement called Sulforaphane (SF) or a placebo (product without any supplement content) over a period of twelve months in order to determine if it is a useful dietary supplement for prevention of lung cancer in humans. The main goals of this research study are: 1. To learn about the effects of giving Sulforaphane (SF) to former smokers who are still at high risk of developing cancer due to their smoking history and whether or not their condition improves, stays the same or becomes worse after Sulforaphane (SF) is given. 2. To learn whether Sulforaphane (SF) might reverse some of the lung cell changes associated with future development of lung cancer.
Primary Outcome
To explore if daily oral dose of 120 micromole SF can modulate the changes in bronchial dysplasia from endoscopic biopsies in former smokers at high risk for lung cancer. All bronchial biopsies were formalin fixed, paraffin embedded, and H\&E stained for subsequent morphologic evaluation and classification defined by the World Health Organization The scale to score the biopsy: 1= normal; 2= reserve cell hyperplasia; 3 = squamous metaplasia; 4 = mild dysplasia; 5 = moderate dysplasia; 6 = severe
Conditions Studied
Interventions
- DRUG Placebo
- DIETARY_SUPPLEMENT Sulforaphane
Study Locations (1)
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2018-01-25 |
| Est. Completion | 2023-02-17 |
| Phase | Phase 2 |
What the finished NCT03232138 record still lists
NCT03232138 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03232138 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03232138 about?
NCT03232138 is a clinical study titled "Clinical Trial of Lung Cancer Chemoprevention With Sulforaphane in Former Smokers". This research study involves taking an experimental anti-cancer dietary supplement called Sulforaphane (SF) or a placebo (product without any supplement content) over a period of twelve months in order to determine if it is a useful dietary supplement for prevention of lung cancer in humans. The ma...
What is the current status of trial NCT03232138?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2018-01-25. Estimated completion is 2023-02-17.
What conditions does trial NCT03232138 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT03232138?
The interventions under investigation include: Placebo (DRUG), Sulforaphane (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03232138?
This trial is sponsored by Jian-Min Yuan, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03232138 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03232138's enrollment target sits among peer trials
43 289th of 409 higher than 120 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Novel Treatment Combinations in Patients With Lung Cancer
RECRUITING · Phase 2
-
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI